Cardio3 Biosciences appoints Dr. Warren Sherman as Chief Medical Officer
23 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014...
List view / Grid view
News
Masters Speciality Pharma signs exclusivity agreement with Speciality European Pharma for the exclusive distribution of Mitocin®/Mitem® 20mg (mitomycin)
23 October 2014 | By Masters Speciality Pharma
Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden...
Santen announces positive outcome of the European Decentralized Procedure for approval of TAPTIQOM®
23 October 2014 | By Santen
Santen GmbH. announced the positive outcome of the Decentralized Procedure (DCP) for TAPTIQOM® in Europe...
Public Health Sector offers immense opportunities for global wound care market
23 October 2014 | By Frost & Sullivan
Strong relationships with end users and an effective post sales service strategy must be a priority for wound care companies, says Frost & Sullivan...
Rotary announces US$ 8.4 million in grants to fight polio in Nigeria
22 October 2014 | By Distributed by APO (African Press Organization) on behalf of Rotary International
With a 90 percent reduction in polio cases, Nigeria is close to ending transmission of the poliovirus...
Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
New study demonstrates advances in creating treatment for common childhood blood cancer
22 October 2014 | By NYU Langone Medical Center
Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia...
Allergic conjunctivitis treatment market growing slowly to $1.44 billion by 2018, says GlobalData
22 October 2014 | By GlobalData
The loss of patent exclusivity on several key branded products and the lack of novel drugs will result in minimal growth of the allergic conjunctivitis treatment market, from $1.37 billion in 2013 to $1.44 billion by 2018...
Merck has shown consistent approach to their corporate social responsibility agenda in Africa and India since 2013
22 October 2014 | By Distributed by APO (African Press Organization) on behalf of Merck KGaA
The Merck Capacity Advancement Program was kicked off successfully in 7 sub- Saharan countries...
Multiple scientific posters supporting the efficacy, safety and tolerability of once-daily Latuda® (lurasidone) are presented at the 27th ECNP Congress
22 October 2014 | By Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc
Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions at the 27th European College of Neuropsychopharmacology...
Tanzania to host The Economist Events’ Health Care in Africa 2014
22 October 2014 | By APO (African Press Organization) on behalf of The Economist Events
The Economist Events will be hosting their Health Care in Africa Summit in Dar es Salaam, Tanzania at the Hyatt Regency, The Kilimanjaro on November 18th and 19th 2014...
Roche invests for the future in its Basel site
22 October 2014 | By Roche
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development...
Ebola affecting tours to South Africa
22 October 2014 | By Frost & Sullivan
Etienne van Wyk, Programme Manager for Healthcare at Frost & Sullivan Africa, comments on the current outbreak and its long term implications...
Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
21 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer...
Sartorius grows in order intake, sales revenue and earnings
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, successfully closed the first nine months of 2014 with substantial gains.
